JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1999; 33:1895-1902
© 1999 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hohnloser, S. H.
Right arrow Articles by Mauß, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hohnloser, S. H.
Right arrow Articles by Mauß, O.

CLINICAL STUDIES

Prevalence, characteristics and prognostic value during long-term follow-up of nonsustained ventricular tachycardia after myocardial infarction in the thrombolytic era

Stefan H. Hohnloser, MD, FACCa, Thomas Klingenheben, MDa, Markus Zabel, MDa, Matthias Schöpperl, MDa and Oliver Mauß, MSca

a Division of Cardiology, Department of Medicine, J.W. Goethe University, Frankfurt, Germany

Manuscript received July 23, 1998; revised manuscript received January 25, 1999, accepted February 15, 1999.

Reprint requests and correspondence: Dr. Stefan H. Hohnloser, Department of Medicine, Division of Cardiology, J.W. Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
hohnloser{at}em.uni-frankfurt.de

OBJECTIVES

The purpose of this study was to determine the prevalence, characteristics and the predictive value of nonsustained ventricular tachycardia (VT) for subsequent death and arrhythmic events after acute myocardial infarction (AMI).

BACKGROUND

Nonsustained VT has been linked to an increased risk for sudden death in coronary patients. It is unknown whether this parameter can be used for selection of high-risk patients to receive an implantable defibrillator for primary prevention of sudden death in patients shortly after AMI.

METHODS

In 325 consecutive infarct survivors, 24-h Holter monitoring was performed 10 ± 6 days after AMI. All patients underwent coronary angiography, determination of left ventricular function and assessment of heart rate variability (HRV). Mean follow-up was 30 ± 22 months.

RESULTS

There was a low prevalence (9%) of nonsustained VT shortly after AMI. Nonsustained VT together with depressed left ventricular ejection fraction (LVEF) was found in only 2.4% of patients. During follow-up, 25 patients reached one of the prospectively defined end points (primary composite end point of cardiac death, sustained VT or resuscitated ventricular fibrillation; secondary end point: arrhythmic events). Kaplan Meier event probability analyses revealed that only HRV, LVEF and status of the infarct-related artery were univariate predictors of death or arrhythmic events. The presence of nonsustained VT carried a relative risk of 2.6 for the primary study end point but was not a significant predictor if only arrhythmic events were considered. On multivariate analysis, only HRV, LVEF and the status of the infarct artery were found to be independently related to the primary study end point.

CONCLUSIONS

There is a low prevalence of nonsustained VT shortly after AMI. Only 2% to 3% of all infarct survivors treated according to contemporary guidelines demonstrate both depressed LVEF and nonsustained VT. The predictive value of nonsustained VT for subsequent mortality and arrhythmic events is inferior to that of impaired autonomic tone, LVEF or infarct-related artery patency. Accordingly, the use of nonsustained VT to select patients for primary implantable cardioverter/defibrillator prevention trials shortly after AMI appears to be limited.

Abbreviations and Acronyms
  AMI = acute myocardial infarction
  CAST = cardiac arrythmia suppression trial
  CK = creatine kinase
  HRV = heart rate variability
  ICD = implantable cardioverter/defibrillator
  LVEF = left ventricular ejection fraction
  MADIT = multicenter automatic defibrillator implantation trial
  PTCA = percutaneous transluminal coronary angioplasty
  SDNN = standard deviation of normal-to-normal intervals
  TIMI = thrombolysis in myocardial infarction
  VF = ventricular fibrillation
  VT = ventricular tachycardia




This article has been cited by other articles:


Home page
EuropaceHome page
P.A. Scott, S. Gorman, N.P. Andrews, P.R. Roberts, and P.R. Kalra
Estimation of the requirement for implantable cardioverter defibrillators for the primary prevention of sudden cardiac death post-myocardial infarction based on UK national guidelines (2006)
Europace, April 1, 2008; 10(4): 453 - 457.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. J. Bunch, S. H. Hohnloser, and B. J. Gersh
Mechanisms of Sudden Cardiac Death in Myocardial Infarction Survivors: Insights From the Randomized Trials of Implantable Cardioverter-Defibrillators
Circulation, May 8, 2007; 115(18): 2451 - 2457.
[Full Text] [PDF]


Home page
Med Decis MakingHome page
J. J. Bailey, M. Hodges, and T. R. Church
Decision to Implant a Cardioverter Defibrillator after Myocardial Infarction: The Role of Ejection Fraction v. Other Risk Factor Markers
Med Decis Making, March 1, 2007; 27(2): 151 - 160.
[Abstract] [PDF]


Home page
Eur Heart JHome page
D. E. Hofsten, K. Wachtell, B. Lund, H. Molgaard, K. Egstrup, and on behalf of the DANAMI-2 Investigators
Prevalence and prognostic implications of non-sustained ventricular tachycardia in ST-segment elevation myocardial infarction after revascularization with either fibrinolysis or primary angioplasty
Eur. Heart J., February 2, 2007; 28(4): 407 - 414.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
H. Lorenz, C. Junger, K. Seidl, A. Gitt, S. Schneider, R. Schiele, H. Wienbergen, R. Winkler, M. Gottwik, W. Delius, et al.
Do statins influence the prognostic impact of non-sustained ventricular tachycardia after ST-elevation myocardial infarction?
Eur. Heart J., June 1, 2005; 26(11): 1078 - 1085.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
T. H. Makikallio, P. Barthel, R. Schneider, A. Bauer, J. M. Tapanainen, M. P. Tulppo, G. Schmidt, and H. V. Huikuri
Prediction of sudden cardiac death after acute myocardial infarction: role of Holter monitoring in the modern treatment era
Eur. Heart J., April 2, 2005; 26(8): 762 - 769.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
C. J. Plummer, R. J. Irving, and J. M. McComb
The incidence of implantable cardioverter defibrillator indications in patients admitted to all coronary care units in a single district
Europace, January 1, 2005; 7(3): 266 - 272.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
D. G Katritsis and A.J. Camm
Nonsustained ventricular tachycardia: where do we stand?
Eur. Heart J., July 1, 2004; 25(13): 1093 - 1099.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
E. F. Lewis, L. A. Moye, J. L. Rouleau, F. M. Sacks, J. M. O. Arnold, J. W. Warnica, G. C. Flaker, E. Braunwald, and M. A. Pfeffer
Predictors of late development of heart failure in stable survivors of myocardial infarction: The CARE study
J. Am. Coll. Cardiol., October 15, 2003; 42(8): 1446 - 1453.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. V. Huikuri, J. M. Tapanainen, K. Lindgren, P. Raatikainen, T. H. Makikallio, K. E. Juhani Airaksinen, and R. J. Myerburg
Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era
J. Am. Coll. Cardiol., August 20, 2003; 42(4): 652 - 658.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
C J Plummer and J M McComb
An audit of the implications of implementing NICE guidance on the use of implantable cardioverter-defibrillators
Heart, July 1, 2003; 89(7): 787 - 788.
[Full Text] [PDF]


Home page
CirculationHome page
S. H. Hohnloser and B. J. Gersh
Changing Late Prognosis of Acute Myocardial Infarction: Impact on Management of Ventricular Arrhythmias in the Era of Reperfusion and the Implantable Cardioverter-Defibrillator
Circulation, February 25, 2003; 107(7): 941 - 946.
[Full Text] [PDF]


Home page
BMJHome page
J. M McComb and A J. Camm
Primary prevention of sudden cardiac death using implantable cardioverter defibrillators
BMJ, November 9, 2002; 325(7372): 1050 - 1051.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. J. Bailey, A. S. Berson, H. Handelsman, and M. Hodges
Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction
J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1902 - 1911.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S.G. Priori, E. Aliot, C. Blomstrom-Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, A.J. Camm, R. Cappato, S.M. Cobbe, C. Di Mario, et al.
Task Force on Sudden Cardiac Death of the European Society of Cardiology
Eur. Heart J., August 2, 2001; 22(16): 1374 - 1450.
[PDF]


Home page
CirculationHome page
M. T. La Rovere, G. D. Pinna, S. H. Hohnloser, F. I. Marcus, A. Mortara, R. Nohara, J. T. Bigger Jr, A. J. Camm, and P. J. Schwartz
Baroreflex Sensitivity and Heart Rate Variability in the Identification of Patients at Risk for Life-Threatening Arrhythmias : Implications for Clinical Trials
Circulation, April 24, 2001; 103(16): 2072 - 2077.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1999 by the American College of Cardiology Foundation.